NASDAQ · INO
Inovio Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for INO: Nov 9, 2026
Inovio Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.2. The reported EPS for the same quarter last year was $-0.44.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.20 | $-0.19 | $-0.20 | 2 |
| Dec 2026 | $-0.18 | $-0.18 | $-0.18 | 2 |
| Mar 2027 | $-0.18 | $-0.15 | $-0.20 | 2 |
| Jun 2027 | $-0.13 | $-0.08 | $-0.18 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat · The Motley Fool- Zacks · Oct 8, 10:45 AM EDTFDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast CancerPfizer's Tukysa combo regimen wins FDA approval for frontline maintenance breast cancer treatment, extending its use beyond the second-line setting.
- Zacks · Oct 5, 10:44 AM EDTPGEN Stock Up More Than 50% in 3 Months: Here's What You Should KnowPrecigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
- Zacks · Sep 30, 11:08 AM EDTPGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
- RTTNews · Sep 29, 5:33 AM EDTBiotech Stocks Facing FDA Decision In October 2026(RTTNews) – The FDA's October decision calendar looks relatively light, with only a limited number of PDUFA dates scheduled.
- Zacks · Sep 24, 10:17 AM EDTCan PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
- Zacks · Sep 14, 10:12 AM EDTPrecigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
- MarketBeat · Sep 11, 9:02 AM EDTInovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date LoomsPalantir Bulls Face a Reality Check Before EarningsInovio Pharmaceuticals (NASDAQ:INO) said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, wi
- Zacks · Sep 10, 11:03 AM EDTCan Papzimeos Drive Precigen's Growth Through the Rest of 2026?Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.
- MarketBeat · Sep 10, 7:02 AM EDTInovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRPPalantir Bulls Face a Reality Check Before EarningsInovio Pharmaceuticals (NASDAQ:INO) is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzger
- The Motley Fool · Aug 12, 8:58 PM EDTInovio (INO) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 12, 8:03 PM EDTInovio Pharmaceuticals Q2 Earnings Call HighlightsPalantir Bulls Face a Reality Check Before EarningsInovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an investigational treatment for recurrent
- Zacks · Aug 5, 8:50 AM EDTBet on 5 Top-Ranked Stocks With Rising P/ETap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Inovio Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.